Academic Partnerships The company has expanded academic collaborations with Michigan State University through a sponsored research agreement and Appointed Anna Moore as Chair of its Scientific Advisory Board, creating compelling entry points for sponsored research deals, joint grants, and access to university partnerships for BD outreach.

Virotherapy Portfolio TransCode's exclusive license to three oncolytic virus candidates UIO-524, UIO-525, and UIO-526 provides multiple business development opportunities for co-development, licensing, or milestone-based arrangements with biotech and pharma partners seeking virotherapy and immuno-oncology assets.

Metastasis Target Lead candidate TTX-MC138 targets miRNA-10b, a master regulator of metastatic cell viability across diverse cancers, positioning TransCode to pursue broad oncology collaborations or metastasis-focused development programs with strategic partners.

Financial Readiness With a financing of 1.5 million and revenue in the 1-10 million range, TransCode demonstrates early-stage liquidity and a growth runway suitable for sponsor-funded research, joint development agreements, and milestone-driven partnerships.

Leadership Momentum New leadership appointments, including the Chief Executive Officer and board additions, signal strategic execution and governance maturation, increasing partner confidence and opening doors for long-term development alliances and co-investment opportunities.